{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T14:19:48Z","timestamp":1768227588942,"version":"3.49.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Composite lymphoma has been rarely reported due to its low incidence. The treatment of composite lymphoma depends on the specific lymphoma subtypes involved. No standardized therapeutic regimen has been established. We tried to treat the patient with Sintilimab+AVD for composite Hodgkin lymphoma and follicular lymphoma, after which the patient was able to maintain a normal quality of life and achieved partial remission (PR). To the best of our knowledge, this is the first attempt to use the PD-1 inhibitor combined with the AVD regimen successfully for the treatment of composite Hodgkin lymphoma and follicular lymphoma.<\/jats:p>","DOI":"10.3389\/fonc.2025.1692954","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T11:13:13Z","timestamp":1768216393000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Sintilimab combined with AVD for the treatment of composite Hodgkin lymphoma and follicular lymphoma: a case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Huami","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changqian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianjie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01799","article-title":"Classic hodgkin lymphoma in adolescents and young adults","volume":"42","author":"Kelly","year":"2024","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II checkMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic hodgkin lymphoma: the randomized phase 2 german hodgkin study group NIVAHL trial","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019254","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic hodgkin lymphoma: safety and efficacy in the phase II checkMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008116","article-title":"Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma","volume":"7","author":"Allen","year":"2023","journal-title":"Blood Adv"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab-AVD in advanced stage classic hodgkin lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1046\/j.1365-2559.2000.00895.x","article-title":"The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997","volume":"36","author":"Harris","year":"2000","journal-title":"Histopathology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.7.2202","article-title":"Follicular large cell lymphoma: An aggressive lymphoma that often presents with favorable prognostic features","volume":"93","author":"Rodriguez","year":"1999","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2298","article-title":"A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival","volume":"101","author":"Hans","year":"2003","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1120967","article-title":"Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi","volume":"13","author":"Margiotta-Casaluci","year":"2023","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic Malignancy: preliminary results of a phase ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197709)40:3<959::aid-cncr2820400302>3.0.co;2-3","article-title":"Composite lymphoma","volume":"40","author":"Kim","year":"1977","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyv101","article-title":"Clinicopathological features of classical Hodgkin lymphoma in patients \u2265 40 years old, with special reference to composite cases","volume":"45","author":"Maeshima","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/PAS.0000000000001780","article-title":"Plasticity of mature B cells between follicular and classic hodgkin lymphomas: A series of 22 cases expanding the spectrum of transdifferentiation","volume":"46","author":"Trecourt","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2014.08.016","article-title":"Hodgkin-like peripheral T-cell lymphoma (PTCL) with preserved Hodgkin-like lesions at autopsy: A case report with an interesting clinical course","volume":"211","author":"Mori","year":"2015","journal-title":"Pathol Res Pract"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225695","article-title":"Plasticity in classical hodgkin composite lymphomas: A systematic review","volume":"14","author":"Trecourt","year":"2022","journal-title":"Cancers"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.11406\/rinketsu.63.544","article-title":"Transformation of follicular lymphoma to classical Hodgkin lymphoma during observation","volume":"63","author":"Ishida","year":"2022","journal-title":"Rinsho Ketsueki"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e254475","DOI":"10.1136\/bcr-2022-254475","article-title":"An Atypical relapsing follicular lymphoma to composite Hodgkin\u2019s lymphoma","volume":"16","author":"Abadir","year":"2023","journal-title":"BMJ Case Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2021.1967083","article-title":"Successful PD-1 inhibitor treatment in a patient with refractory transformed follicular lymphoma who failed to respond to CAR-T cell therapy: a case report and literature review","volume":"22","author":"Zheng","year":"2021","journal-title":"Cancer Biol Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2460","article-title":"Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis","volume":"70","author":"Cheung","year":"2010","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1159\/000475530","article-title":"Tumor heterogeneity in lymphomas: A different breed","volume":"85","author":"Sch\u00fcrch","year":"2018","journal-title":"Pathobiology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e281","DOI":"10.1038\/bcj.2015.1","article-title":"PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival","volume":"5","author":"Yang","year":"2015","journal-title":"Blood Cancer J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403841","article-title":"Insights into the multistep transformation process of lymphomas: IgH-associated translocations and tumor suppressor gene mutations in clonally related composite Hodgkin\u2019s and non-Hodgkin\u2019s lymphomas","volume":"19","author":"Schmitz","year":"2005","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3960\/jslrt.47.9","article-title":"Demonstration of chimeric DNA of bcl-2 and immunoglobulin heavy chain in follicular lymphoma and subsequent Hodgkin lymphoma from the same patient","volume":"47","author":"Nakamura","year":"2007","journal-title":"J Clin Exp Hematop"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000002225","article-title":"Patients with classic hodgkin lymphoma and follicular lymphoma compared to single Malignancy controls","volume":"48","author":"Cotta","year":"2024","journal-title":"Am J Surg Pathol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1692954\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T11:13:14Z","timestamp":1768216394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1692954\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":26,"alternative-id":["10.3389\/fonc.2025.1692954"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1692954","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1692954"}}